General Medicine and Primary Care

Host: Richard Johnson, MD

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD

Guest: John K. Botson, MD, RPh

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Abdul Abdellatif, MD, FASN

Guest: Richard Johnson, MD

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Abdul Abdellatif, MD, FASN

Guest: John K. Botson, MD, RPh

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD

Guest: Abdul Abdellatif, MD, FASN

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Richard Johnson, MD

Guest: Brittany Weber, MD, PhD

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Host: Abdul Abdellatif, MD, FASN

Guest: Richard Johnson, MD

This activity is no longer available for continuing education credit.

Conventional oral urate-lowering therapies frequently to fail to achieve target serum uric acid (sUA) levels in patients with chronic kidney disease and uncontrolled refractory gout. This can lead to increased urate burden and complications, including worsening kidney disease, cardiovascular events, and metabolic syndrome. Tune in to find out how to incorporate targeted therapies when managing uncontrolled refractory gout and improve your patients’ quality of life.

Guest: Genevieve Hofmann, NP

Menopause can impact everyday life, and many women go untreated for their menopausal symptoms. To learn more about some of the complex issues surrounding menopause management, join Dr. Genevieve Hofmann, Women’s Health Nurse Practitioner, Certified Menopause Clinician, and Assistant Professor of OB/GYN Health at the University of Colorado School of Medicine, who will be discussing these strategies at the 2023 Annual NPWH Women’s Healthcare Conference.

Guest: Jennifer Herrmeyer, RN

Approximately less than 30 percent of domestic violence patients will seek care for their injuries, so it’s important for us to reach out to those in need. How can we be better at identifying and caring for these patients? Tune in to learn more with Ms. Jennifer Herrmeyer, Emergency Department Nurse at Hennepin Healthcare in Minneapolis, Minnesota.

Host: John Buse, MD, PhD

Guest: David Cherney, MD, PhD

There have been several major advances regarding the management of chronic kidney disease in patients with type 2 diabetes over the last 5 years, leading Dr. David Cherney and a team of authors to publish a narrative review on how to best manage these patients using the latest treatment options like SGLT2 inhibitors and non-steroidal MRAs. Tune in to hear him share key highlights from the review with Dr. John Buse. Dr. Cherney is a Professor of Medicine at the University of Toronto and the Director of the Renal Physiology Laboratory at University Health Network in Canada.